Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

4Life Research wants to protect the health of bipeds and quadrupeds alike. The multilevel marketing company manufactures nutritional supplements for humans and animals and sells them through its global network of independent distributors. The company's flagship product is Transfer Factor, a supplement made from egg yolks and cow colostrum that is meant to enhance the body's immune system. The firm makes Transfer Factor formulations for humans, dogs, cats, horses, and livestock. The privately-held company was founded in 1998 by CEO David Lisonbee, who had previous experience with multi-level marketing organizations.

ASI Technology Corporation was incorporated in 1931 and is based in Henderson, Nevada. ASI Technology Corporation, together with its subsidiaries, operates as a specialty finance company. The company offers commercial and venture capital loans, as well as provides direct finance leasing services. It also focuses on the development of plasma technology for sterilization and decontamination. The company's patented method uses low voltage to produce high volumes of atmospheric pressure plasma, also known as room temperature or cold plasma.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

GelStat Corporation engages in the development and marketing of over the counter and other nonprescription consumer health care products for pain and inflammation. It markets GelStat Migraine, a homeopathic drug, for the treatment of migraine and migraine-like headaches, as well as GelStat Arthritis, a sublingual dissolving tablet for the treatment of pain and associated symptoms of arthritis. The company is also developing other products that are in the final stages of development, which include GelStat Sinus for the remedy of nasal and/or sinus congestion, irritation, pressure, and sinus headache; and GelStat Sleep for promoting restful sleep. The company sells its products to regional and national retailers, wholesalers, specialty distributors, and catalog merchandisers in the United States directly and through sales brokers. GelStat Corporation is based in Bloomington, Minnesota.

Protide Pharmaceuticals is pro-cell. The firm focuses on developing new technologies for cellular and transfusion therapies, including gene therapies, to treat cancer and genetic disorders and to improve cell transplantation and engineering. To fund its work, Protide sells nearly 20 products under the Celox Laboratories brand to its academic, drug, and diagnostic research clients around the world. These products include serum-free growth mediums and supplements, as well as solutions used to cryopreserve cells and tissues. ICN Pharmaceuticals has a non-exclusive global marketing agreement for certain products. Protide also has a private-label manufacturing deal with a division of Sigma-Aldrich.

Bioniche Life Sciences is seeking its niche in the development of drugs for both humans and animals. The firm has three divisions: Human Health, Animal Health, and Food Safety. The Bioniche Animal Health division sells products to improve livestock breeding and to boost livestock immunity without antibiotics. Bioniche's Food Safety division works to improve food and water quality by developing technology to prevent infections and diseases in animals that are passed on to humans. The company's Bioniche Therapeutics segment is developing pharmaceuticals to help humankind; it focuses on urology, oncology, and immune system disorders.

DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a development stage pharmaceutical company that acquires therapeutic molecules and medical technologies from third parties, and advances their clinical development for later sale to pharmaceutical and biotechnology companies. DARA focuses on two drug development programs: KRN5500 for neuropathic pain in cancer patients and DB959 for type 2 diabetes. On February 12, 2008, Point and DARA BioSciences, Inc. completed their merger transaction, in which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with and into DARA BioSciences, Inc.

USANA Health Sciences was founded in 1992 and is headquartered in Salt Lake City, Utah. USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence, gentle daily cleanser, hydrating toner, daytime protective emulsion, eye nourisher, night renewal, serum intensive, rice bran polisher, creme masque, revitalizing shampoo, nourishing conditioner, firming body nourisher, energizing shower gel, and intensive hand therapy. USANA Health Sciences also provides resource materials and sales tools, including product brochures and business forms, as well as sells reprints of other commercial publications. The company distributes its products through network marketing in the United States, Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, South Korea, the United Kingdom, and the Netherlands.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.